# SEARCH REQUEST FORM

Name:

Number: 08)

Date: \_57

Phone: 308-4550 Art Unit: 1209

# Search Topic:

Please write a detailed statement of search topic. Describe specifically as possible the subject matter to be searched. Define any terms that may have a special meaning. Give examples or relevant citations, authors keywords, etc., if known. For sequences, please attach a copy of the sequence. You may include a copy of the broadest and/or most relevant claim(s).

Compounds :

Simplest structure:

See full detinitions R', R' R', attacked

ad1: 5441

STIC

CM-1

Pre-S

-BUP 13

# STAFF USE ONLY

Date completed: Searcher: Terminal time:. Elapsed time: .

Search S	ite
	(
	I

Vendors	

 IG Suite
 STN

Dialog

APS

CPU time:	 Type of Search
Total time:	N.A.

_	N.A. Sequence	
	A A Coquence	

 Geninfo
 SDC
DARC/Ouestel

Number of Databases	s:

-
 Structure
Ribliographic

D. 110,	Q 000101
Other	

Number of Searches: -

#### => d his

(FILE 'HCAPLUS' ENTERED AT 09:49:52 ON 22 MAY 1997)
DEL HIS Y

FILE 'REGISTRY' ENTERED AT 09:50:12 ON 22 MAY 1997 ACT CLARDY/A

-----

L1 STR

L2 SCR 1701 OR 1192

L3 SCR 1700 AND 497 AND 1834 AND 2005 AND 1838

L4 22 SEA FILE=REGISTRY SSS FUL L1 AND L3 AND L2

----<del>-</del>

FILE 'HCAPLUS' ENTERED AT 09:50:46 ON 22 MAY 1997

L5 18 S L4

FILE 'CAOLD' ENTERED AT 09:50:53 ON 22 MAY 1997

L6 3 S L4

FILE 'REGISTRY' ENTERED AT 09:51:01 ON 22 MAY 1997

=> fil reg

FILE 'REGISTRY' ENTERED AT 09:51:12 ON 22 MAY 1997 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 1997 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 16 MAY 97 HIGHEST RN 189123-98-6 DICTIONARY FILE UPDATES: 21 MAY 97 HIGHEST RN 189123-98-6

TSCA INFORMATION NOW CURRENT THROUGH DECEMBER 1996

Please note that search-term pricing does apply when conducting SmartSELECT searches.

# => d his 11-14

(FILE 'HCAPLUS' ENTERED AT 09:49:52 ON 22 MAY 1997)
DEL HIS Y

FILE 'REGISTRY' ENTERED AT 09:50:12 ON 22 MAY 1997 ACT CLARDY/A

-----

L1 STR

L2 SCR 1701 OR 1192

L3 SCR 1700 AND 497 AND 1834 AND 2005 AND 1838

L4 22 SEA FILE=REGISTRY SSS FUL L1 AND L3 AND L2

=> d que stat 14

L1 STR

0

VAR G1=AK/CB
VAR G2=O/S
VAR G3=OH/H
VAR G4=H/C/CB
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT IS MCY AT 6
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES: RING(S) ARE ISOLATED OR EMBEDDED NUMBER OF NODES IS 10

STEREO ATTRIBUTES: NONE

L2 SCR 1701 OR 1192

L3 SCR 1700 AND 497 AND 1834 AND 2005 AND 1838 L4 22 SEA FILE=REGISTRY SSS FUL L1 AND L3 AND L2

100.0% PROCESSED 81743 ITERATIONS 22 ANSWERS

SEARCH TIME: 00.01.22

=> d ide can 14 1-22

L4 ANSWER 1 OF 22 REGISTRY COPYRIGHT 1997 ACS

RN 161023-70-7 REGISTRY

CN Benzenepropanoic acid, .beta.-[[2-(.beta.-D-glucopyranosylamino)phenyl]thio]-.alpha.-hydroxy-4-methoxy-, monosodium salt, [S-(R\*,S\*)]- (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C22 H27 N O9 S . Na

SR CA

LC STN Files: CA, CAPLUS

Absolute stereochemistry. Rotation (+).

Na

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 122:160270

L4 ANSWER 2 OF 22 REGISTRY COPYRIGHT 1997 ACS

RN 161023-68-3 REGISTRY

CN Benzenepropanoic acid, .beta.-[[2-(.beta.-D-

glucopyranosylamino)phenyl]thio]-.alpha.-hydroxy-4-methoxy-,

 $[S-(R^*,S^*)]-(9CI)$  (CA INDEX NAME)

FS STEREOSEARCH

MF C22 H27 N O9 S

SR CA

LC STN Files: CA, CAPLUS

Absolute stereochemistry. Rotation (+).

1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 122:160270

L4 ANSWER 3 OF 22 REGISTRY COPYRIGHT 1997 ACS

RN 156626-51-6 REGISTRY

CN D-Glucose, 4,6-O-(2-methoxy-1-methyl-2-oxoethylidene)-3-O-methyl-, (S)- (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C11 H18 O8

SR CA

LC STN Files: CA, CAPLUS

### Absolute stereochemistry.

1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

### REFERENCE 1: 121:109442

L4 ANSWER 4 OF 22 REGISTRY COPYRIGHT 1997 ACS

RN 147511-68-0 REGISTRY

CN Benzenepropanoic acid, .beta.-[[2-(D-glucopyranosylamino)phenyl]thio ]-.alpha.-hydroxy-4-methoxy-, monosodium salt, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

MF C22 H27 N O9 S . Na

SR CA

LC STN Files: CA, CAPLUS

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

# REFERENCE 1: 118:233780

L4 ANSWER 5 OF 22 REGISTRY COPYRIGHT 1997 ACS

RN 147364-23-6 REGISTRY

CN Benzenepropanoic acid, .beta.~[[2-(D-glucopyranosylamino)pheny1]thio ]-.alpha.-hydroxy-4-methoxy-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

MF C22 H27 N O9 S

SR CA

LC STN Files: CA, CAPLUS

1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

#### REFERENCE 1: 118:233780

L4 ANSWER 6 OF 22 REGISTRY COPYRIGHT 1997 ACS

RN 146942-12-3 REGISTRY

CN D-Glucose, 4,6-O-(phenylmethylene)-, 3-acetate (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C15 H18 O7

SR CA

LC STN Files: CA, CAPLUS, CASREACT

1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

#### REFERENCE 1: 118:192109

L4 ANSWER 7 OF 22 REGISTRY COPYRIGHT 1997 ACS

RN 140646-83-9 REGISTRY

CN Benzenepropanoic acid, .alpha.-hydroxy-.beta.-[(3-oxopropyl)thio]-2-(8-phenyloctyl)-, [S-(R\*,S\*)]- (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C26 H34 O4 S

SR CA

LC STN Files: CA, CAPLUS, TOXLIT, USPATFULL

# Absolute stereochemistry.

1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

# REFERENCE 1: 117:14418

L4 ANSWER 8 OF 22 REGISTRY COPYRIGHT 1997 ACS

RN 128305-69-1 REGISTRY

CN Benzenepropanoic acid, .alpha., 4-dihydroxy-.beta.-[(2nitrophenyl)thio]- (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C15 H13 N O6 S

SR CA

LC STN Files: CA, CAPLUS

- 1 REFERENCES IN FILE CA (1967 TO DATE)
- 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

#### REFERENCE 1: 113:76603

L4 ANSWER 9 OF 22 REGISTRY COPYRIGHT 1997 ACS

RN 127981-91-3 REGISTRY

CN Benzenepropanoic acid, .beta.-[(2-aminophenyl)thio]-.alpha.-hydroxy-4-methoxy-, [S-(R\*,R\*)]-, compd. with [S-(R\*,R\*)]-2-amino-1-[4-(methylthio)phenyl]-1,3-propanediol (1:1) (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 1,3-Propanediol, 2-amino-1-[4-(methylthio)phenyl]-, [S-(R\*,R\*)]-,
 [S-(R\*,R\*)]-.beta.-[(2-aminophenyl)thio]-.alpha.-hydroxy-4 methoxybenzenepropanoate (salt) (9CI)

FS STEREOSEARCH

MF C16 H17 N O4 S . C10 H15 N O2 S

SR CA

LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 42399-48-4

CMF C16 H17 N O4 S

# Absolute stereochemistry.

CM 2

CRN 16854-32-3 CMF C10 H15 N O2 S

Absolute stereochemistry.

1 REFERENCES IN FILE CA (1967 TO DATE)


1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 113:40161

L4 ANSWER 10 OF 22 REGISTRY COPYRIGHT 1997 ACS

RN 120433-69-4 REGISTRY
CN Benzenepropanoic acid, .beta.-[(2-aminophenyl)thio]-.alpha.,4-dihydroxy-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C15 H15 N O4 S
SR CA
LC STN Files: CA, CAPLUS, TOXLIT

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 110:219194

L4 ANSWER 11 OF 22 REGISTRY COPYRIGHT 1997 ACS

RN 120427-55-6 REGISTRY

CN Benzenepropanoic acid, .alpha.-hydroxy-.beta.-[(4-hydroxyphenyl)thio]-2-(8-phenyloctyl)- (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C29 H34 O4 S

SR CA

LC STN Files: CA, CAPLUS, USPATFULL

2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 115:49105

REFERENCE 2: 110:212373

L4 ANSWER 12 OF 22 REGISTRY COPYRIGHT 1997 ACS

RN 112670-08-3 REGISTRY

CN D-Gulose, 4,6-0-(1-methylethylidene)-3-0-(phenylmethyl)- (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C16 H22 O6

SR CA

LC STN Files: CA, CAPLUS, CASREACT

Absolute stereochemistry.

1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 108:75759

L4 ANSWER 13 OF 22 REGISTRY COPYRIGHT 1997 ACS

RN 105453-42-7 REGISTRY

CN D-Glucose, 4,6-O-ethylidene-, 3-acetate, (R)- (9CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C10 H16 O7

SR CA

LC STN Files: CA, CAPLUS, CASREACT

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 105:227147

L4 ANSWER 14 OF 22 REGISTRY COPYRIGHT 1997 ACS

RN 103101-90-2 REGISTRY

CN D-Glucose, 4,6-0-benzylidene-, 3-ester with N-carboxy-DL-norleucine N-benzyl ester (7CI) (CA INDEX NAME)

MF C27 H33 N O9

SR CAOLD

LC STN Files: CAOLD

# 2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L4 ANSWER 15 OF 22 REGISTRY COPYRIGHT 1997 ACS

RN 101173-91-5 REGISTRY

CN D-Glucose, 4,6-O-benzylidene-, 3-ester with N-carboxyglycine N-benzyl ester (7CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C23 H25 N O9

SR CAOLD

LC STN Files: CAOLD

Absolute stereochemistry.

# 2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L4 ANSWER 16 OF 22 REGISTRY COPYRIGHT 1997 ACS

RN 100021-32-7 REGISTRY

CN D-Glucose, 4,6-O-ethylidene-, 3-acetate (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C10 H16 O7

SR CA

LC STN Files: CA, CAPLUS, CASREACT, CJACS

1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 104:110035

L4 ANSWER 17 OF 22 REGISTRY COPYRIGHT 1997 ACS

RN 96192-70-0 REGISTRY

CN Benzenepropanoic acid, .beta.-[(5-chloro-2-nitrophenyl)thio]-.alpha.-hydroxy-4-methoxy-, [R-(R\*,R\*)]-, compd. with (S)-2,6-diaminohexanal (1:1) (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Hexanal, 2,6-diamino-, (S)-, compd. with [R-(R\*,R\*)]-.beta.-[(5-chloro-2-nitrophenyl)thio]-.alpha.-hydroxy-4-methoxybenzenepropanoic acid (1:1) (9CI)

FS STEREOSEARCH

MF C16 H14 Cl N O6 S . C6 H14 N2 O

LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 96125-23-4

CMF C16 H14 Cl N O6 S

Absolute stereochemistry.

CM 2

CRN 21653-99-6 CMF C6 H14 N2 O

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 103:142026

L4 ANSWER 18 OF 22 REGISTRY COPYRIGHT 1997 ACS

RN 96192-69-7 REGISTRY

CN Benzenepropanoic acid, .beta.-[(5-chloro-2-nitrophenyl)thio]-.alpha.-hydroxy-4-methoxy-, [S-(R\*,R\*)]-, compd. with (S)-2,6-diaminohexanal (1:1) (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Hexanal, 2,6-diamino-, (S)-, compd. with [S-(R\*,R\*)]-.beta.-[(5-chloro-2-nitrophenyl)thio]-.alpha.-hydroxy-4-methoxybenzenepropanoic acid (1:1) (9CI)

FS STEREOSEARCH

MF C16 H14 Cl N O6 S . C6 H14 N2 O

LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 96125-22-3

CMF C16 H14 Cl N O6 S

Absolute stereochemistry.

CM 2

CRN 21653-99-6

CMF C6 H14 N2 O

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 103:142026

L4 ANSWER 19 OF 22 REGISTRY COPYRIGHT 1997 ACS

RN 83158-08-1 REGISTRY

CN D-Glucose, 3-0-2-butenyl-4,6-0-(phenylmethylene)- (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C17 H22 O6

LC STN Files: CA, CAPLUS

Absolute stereochemistry. Double bond geometry unknown.

1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 97:145161

L4 ANSWER 20 OF 22 REGISTRY COPYRIGHT 1997 ACS

RN 75847-75-5 REGISTRY

CN D-Allose, 3-C-phenyl-3-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C19 H22 O6

Absolute stereochemistry.

L4 ANSWER 21 OF 22 REGISTRY COPYRIGHT 1997 ACS

RN 55651-99-5 REGISTRY

CN D-Glucose, 3-O-methyl-4,6-O-(phenylmethylene)- (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C14 H18 O6

LC STN Files: BEILSTEIN\*, CA, CAPLUS, CASREACT (\*File contains numerically searchable property data)

Absolute stereochemistry.

2 REFERENCES IN FILE CA (1967 TO DATE)

2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 109:149900

REFERENCE 2: 82:156596

L4 ANSWER 22 OF 22 REGISTRY COPYRIGHT 1997 ACS

RN 42399-56-4 REGISTRY

CN Benzenepropanoic acid, .beta.-[(2-aminophenyl)thio]-.alpha.-hydroxy-4-methoxy-, [R-(R\*,R\*)]-, compd. with (R)-4-[1-hydroxy-2-

(methylamino)ethyl]-1,2-benzenediol (1:1) (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 1,2-Benzenediol, 4-[1-hydroxy-2-(methylamino)ethyl]-, (R)-, [R-(R\*,R\*)]-.beta.-[(2-aminophenyl)thio]-.alpha.-hydroxy-4-methoxybenzenepropanoate (salt) (9CI)

FS STEREOSEARCH

MF C16 H17 N O4 S . C9 H13 N O3

LC STN Files: CA, CAPLUS

CM 1

CRN 42399-50-8

CMF C16 H17 N O4 S

Absolute stereochemistry.

CM 2

CRN 51-43-4

CMF C9 H13 N O3

Absolute stereochemistry.

1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 79:66331

=> fil hcaplus FILE 'HCAPLUS' ENTERED AT 09:51:53 ON 22 MAY 1997 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 1997 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1967 - 22 May 1997 VOL 126 ISS 21 FILE LAST UPDATED: 22 May 1997 (970522/ED)

To help control your online searching costs, consider using the HCAplus file when using the FSEARCH command or when conducting SmartSELECT searches with large numbers of terms.

Some chemical substances have deleted CAS Registry Numbers. To ensure that you are using the most current CAS Registry Number, and for a more complete search, start your CAS Registry Number search in the REGISTRY file. Then use the L-number answer set from REGISTRY as a search term in HCAplus.

This file contains CAS Registry Numbers for easy and accurate substance identification.

'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE

=> d his 15

L5

(FILE 'REGISTRY' ENTERED AT 09:50:12 ON 22 MAY 1997)

FILE 'HCAPLUS' ENTERED AT 09:50:46 ON 22 MAY 1997 18 S L4

=> d .ca 15 1-18

L5 ANSWER 1 OF 18 HCAPLUS COPYRIGHT 1997 ACS

AN 1995:356912 HCAPLUS

DN 122:160270

TI Method for preparation of D-threo-2-hydroxy-3-(2-aminophenylthio)-3-

(4-methoxyphenyl)propionic acid via resolution as an N-glycoside IN Grynkiewicz, Grzegorz; Gawronski, Jacek; Malinowska, Iwona; Palanowski, Ryszard

PA Instytut Farmaceutiyczny, Pol.

SO Pol., 4 pp. CODEN: POXXA7

PI PL 162457 B1 931231

AI PL 90-284716 900410

DT Patent

LA Polish

OS CASREACT 122:160270

GΙ

Title acid D-I, an intermediate for the drug diltiazem, is prepd. by a new method. The method involves reaction of racemic D,L-I or its esters with D-glucose to form N-glycoside derivs., which are sepd. by crystn. to give optically pure glycosides D-II (R = H, Me, Et). The latter undergo acid hydrolysis of the glycoside and alk. hydrolysis of the ester, if present, by known methods, giving D-I. For example, a mixt. of 16.0 g D,L-I, 13.5 g D-glucose, and 3 mL AcOH in 100 mL MeOH was heated at the b.p. for 1/2 h and cooled to give cryst. D-II (R = H). This was hydrolyzed by dil. aq. HCl (pH 2) at 50.degree., and the mixt. neutralized to pH 3-4, to give 6.7 g (42% of racemate) D-I. In several addnl. examples, also using esters of D,L-I as starting materials, yields of glycosides were typically 40-45%, and hydrolysis yields were typically 80-90%.

161023-68-3P 161023-70-7P

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)

(intermediate; resoln. of threo-hydroxy(aminophenylthio)(methoxyphenyl)propionic acid via N-glycosides)

IC ICM C07C323-63

IT

CC

25-17 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds) Section cross-reference(s): 33

IT 139748-71-3P 160949-69-9P **161023-68-3P** 

161023-70-7P

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)

(intermediate; resoln. of threo-hydroxy(aminophenylthio) (methoxyp henyl)propionic acid via N-glycosides)

- L5 ANSWER 2 OF 18 HCAPLUS COPYRIGHT 1997 ACS
- AN 1994:509442 HCAPLUS
- DN 121:109442
- TI Chemical synthesis of the pyruvic acetal-containing trisaccharide unit of the species-specific glycopeptidolipid from Mycobacterium avium serovariant 8
- AU Bajza, Istvan; Kerekgyarto, Janos; Hajko, Janos; Szilagyi, Laszlo; Liptak, Andras
- CS Inst. Biochem., Lajos Kossuth Univ., Debrecen, H-4010, Hung.
- SO Carbohydr. Res. (1994), 253, 111-20 CODEN: CRBRAT; ISSN: 0008-6215
- DT Journal
- LA English
- OS CJELSEVIER
- GI

- AB The functionalized, pyruvic acetal-contg. haptenic trisaccharide I, a component of the glycolipid from Mycobacterium avium serovar 8 was synthesized.
- IT 156626-51-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (prepn. and reaction of, in synthesis of pyruvic acetal-contg. trisaccharide unit of glycopeptidolipid of Mycobacterium avium)

Ι

- CC 33-4 (Carbohydrates)
  - Section cross-reference(s): 34
- TΤ 30694-99-6P 59054-68-1P 156626-35-6P 156626-36-7P 156626-40-3P 156626-38-9P 156626-39-0P 156626-37-8P 156626-44-7P 156626-43-6P 156626-41-4P 156626-42-5P 156626-45-8P 156626-46**-**9P 156626-47-0P 156626-48-1P

#### 156626-49-2P 156626-51-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (prepn. and reaction of, in synthesis of pyruvic acetal-contg. trisaccharide unit of glycopeptidolipid of Mycobacterium avium)

- L5 ANSWER 3 OF 18 HCAPLUS COPYRIGHT 1997 ACS
- AN 1993:233780 HCAPLUS
- DN 118:233780
- TI New optically active intermediates in the synthesis of diltiazem
- AU Malinowska, Iwona; Eksanow, Kamil; Dabrowska, Jolanta; Jahn, Wanda; Jakubowski, Witold
- CS Pharm. Res. Inst., Warsaw, 01793, Pol.
- SO Acta Pol. Pharm. (1991), 48(3-4), 47-50 CODEN: APPHAX; ISSN: 0001-6837
- DT Journal
- LA English

GΙ

Ι

- The racemate of the propionic acid deriv. I (R = H; R1 = H) refluxed with D-glucose in MeOH/AcOH yielded 40% (2S,3S)-I (R = glucopyranosyl, R1 = H, II), which upon acid hydrolysis gave (2S,3S)-I (R = H, R1 = H) (III). (2S,3S)-I (R = glucopyranosyl, R1 = Et) (IV) was obtained analogously and then converted by alk. hydrolysis into the Na salt of II (V) and by acid hydrolysis into III. IV and Ac2O yielded 81% (2S,3S)-I (R = Ac, R1 = Et) subsequently hydrolyzed with NaOH to (2S,3S)-I (R = Ac, R1 = Et). V and Ac2O in DMF-C5H5N gave the O-Ac deriv. of (2S,3S)-I (R = tetraacetylglucopyranosyl, R1 = H), hydrolyzed to (2S,3S)-I (R = Ac, R1 = H).
- IT 147511-68-0
  - RL: RCT (Reactant))
- IT 147364-23-6P
  - RL: SPN (Synthetic preparation); PREP (Preparation)
     (prepn. of, as chiral intermediate for diltiazem)
- CC 27-1 (Heterocyclic Compounds (One Hetero Atom))
- IT 147511-68-0
  - RL: RCT (Reactant)
- IT 42399-48-4P 125411-72-5P **147364-23-6P** 147364-24-7P
  - 147364-25-8P 147511-67-9P
  - RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of, as chiral intermediate for diltiazem)
- L5 ANSWER 4 OF 18 HCAPLUS COPYRIGHT 1997 ACS
- AN 1993:192109 HCAPLUS
- DN 118:192109

```
TI Selective acylation of 4,6-O-benzylidene glycopyranosides by enzymic catalysis
AU Panza, Luigi; Luisetti, Monica; Crociati, Emanuela; Riva, Sergio
```

AU Paliza, bulgi, bulsecti, monica, clociati, bulantela, kiva,

CS Cent. Stud. Sost. Org. nat., CNR, Milan, 20133, Italy

SO J. Carbohydr. Chem. (1993), 12(1), 125-30 CODEN: JCACDM; ISSN: 0732-8303

DT Journal

LA English

OS CASREACT 118:192109

GΙ

Ph O O O OR OR OH II

AB Benzylidene glycosides I-IV (R = Me, allyl) were regioselectively acylated with CF3CH2O2CCH2CH2Me or AcoCH:CH2 in the prescense of lipase PS from Pseudomonas cepacia.

IT 146942-12-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of, regioselectivity in)

III

CC 33-3 (Carbohydrates)

98392<del>-</del>36-0P IT 107657-07-8P 130464-35-6P 141611-58-7P 144607-28-3P 146942-00-9P 141611-59-8P 144607-27-2P 146942-04-3P 146942-01-0P 146942-02-1P 146942-03-2P 146942-05-4P 146942-06-5P 146942-07-6P 146942-09-8P 146942-11-2P 146942-12-3P 146942-13-4P

RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of, regioselectivity in)

- L5 ANSWER 5 OF 18 HCAPLUS COPYRIGHT 1997 ACS
- AN 1992:414418 HCAPLUS
- DN 117:14418
- TI Antiallergic compositions containing platelet-activating factor antagonists and leukotriene D4 antagonists
- IN O'Donnell, Margaret; Welton, Ann
- PA Hoffmann-La Roche, F., A.-G., Switz.

SO

Eur. Pat. Appl., 16 pp.

```
CODEN: EPXXDW
     EP 469477 A1 920205
PΙ
     R: AT, BE, CH, DE, DK, FR, GB, IT, LI, LU, NL, SE
DS
     EP 91-112577 910726
ΑI
PRAI US 90-561743 900802
DT
     Patent
LА
     English
     A synergistic combination of platelet activating factor (PAF)
AΒ
     antagonists with leukotriene D4 (LTD4) antagonists provides
     protection against allergic reactions, such as antigen-induced
            Guinea pigs were sensitized with an i.p. injection of
     ovalbumin in a saline soln. and administered with a combination of
     5-[3-[4-(2-chlorophenyl)-9-methyl-6H-thieno[3,2-f]1,2,4]triazolo[4,3-f]
     a][1,4]diazepin-2-yl]-2-propynyl]phenanthridin-6(5H)-one (I) (PAF
     antagonist) and (E)-4-[3-[2-(4-cyclobutyl-2-
     thiazolyl)ethenyl]phenylamino]-2,2-diethyl-4-oxobutanoic acid (II)
     (LTD4 antagonist) at 1 mg/kg each before challenge with antigen; a
     survival rate from anaphylactic death at 120 min was 100 %, compared
     to 0 % for groups administered with I or II alone. Formulations
     contg. I and II combinations are given.
     140646-83-9D, mixts. with platelet-activating factor
TΤ
     antagonists
     RL: BIOL (Biological study)
        (antiallergic compns. contg.)
IC
     ICM A61K031-55
     ICS A61K031-44
     A61K031-55, A61K031-425; A61K031-44, A61K031-425
ICI
     63-6 (Pharmaceuticals)
     Section cross-reference(s): 1
     50847-11-5D, mixts. with platelet-activating factor antagonists
ΙT
     96566-25-5D, mixts. with platelet-activating factor antagonists
     98116-53-1D, mixts. with platelet-activating factor antagonists
     98193-06-7D, mixts. with platelet-activating factor antagonists
     103176-67-6D, mixts. with platelet-activating factor antagonists
     103177-37-3D, mixts. with platelet-activating factor antagonists
     104073-72-5D, mixts. with platelet-activating factor antagonists
     105350-26-3D, mixts. with platelet-activating factor antagonists
     106556-34-7D, mixts. with leukotriene D4 antagonists
                                                            111974-60-8D,
     mixts. with platelet-activating factor antagonists
                                                          115621-84-6D,
     mixts. with leukotriene D4 antagonists
                                              116289-53-3D, mixts. with
                                  116781-15-8D, mixts. with leukotriene
     leukotriene D4 antagonists
                      116953-66-3D, mixts. with leukotriene D4
     D4 antagonists
                  117796-52-8D, mixts. with leukotriene D4 antagonists
     antagonists
     118314-35-5D, mixts. with platelet-activating factor antagonists
     120128-20-3D, mixts. with platelet-activating factor antagonists
     120555-31-9D, mixts. with leukotriene D4 antagonists
                                                            122009-61-4D,
     mixts. with platelet-activating factor antagonists
                                                          128312-51-6D,
     mixts. with platelet-activating factor antagonists
                                                          140634-85-1D,
                                                            140634-88-4
     mixts. with leukotriene D4 antagonists
                                              140634-87-3
                                 140646-77-1D, mixts. with leukotriene D4
     140634-89-5
                   140634-90-8
                   140646-78-2D, mixts. with platelet-activating factor
     antagonists
                   140646-79-3D, mixts. with platelet-activating factor
     antagonists
     antagonists
                   140646-80-6D, mixts. with platelet-activating factor
                   140646-81-7D, mixts. with platelet-activating factor
     antagonists
                   140646-82-8D, mixts. with platelet-activating factor
     antagonists
     antagonists 140646-83-9D, mixts. with platelet-activating
```

factor antagonists

factor antagonists

L5

ΑN DN

TI

IN

PΑ SO

PΙ

DS ΑI

DT

LA os

AΒ

ΤТ

TC

CC

TΤ

140646-84-0D, mixts. with platelet-activating

140646-85-1D, mixts. with platelet-activating

```
140667-06-7
                         140667-05-6
                                                      140667-07-8
     factor antagonists
     140667-72-7D, mixts. with leukotriene D4 antagonists
                                                           140709-00-8D,
    mixts. with leukotriene D4 antagonists 140852-24-0D, mixts. with
                                141897-51-0D, mixts. with leukotriene
     leukotriene D4 antagonists
                     141924-18-7D, mixts. with leukotriene D4
     D4 antagonists
                  141980-55-4D, mixts. with leukotriene D4 antagonists
     antagonists
    RL: BIOL (Biological study)
        (antiallergic compns. contg.)
    ANSWER 6 OF 18 HCAPLUS COPYRIGHT 1997 ACS
    1991:449105 HCAPLUS
     115:49105
    Leukotriene antagonists
     Frazee, James Simpson; Gleason, John Gerald; Hall, Ralph Floyd
     SmithKline Beckman Corp., USA
    Eur. Pat. Appl., 39 pp.
     CODEN: EPXXDW
    EP 403249 A1 901219
    R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE
    EP 90-306438 900613
PRAI US 89-366046 890614
     Patent
    English
    MARPAT 115:49105
    RS(0)mCHR1C6H4R2-2 [I; R = aryl, aralkyl, etc.; m = 0, 2; R2 =
     CHX(CH2)nZ; X = OH, alkoxy; n = 0, 1, 2; Z = CO2H, CONH2,
     tetrazolyl, etc.; R2 = alkyl, alkoxy, aralkyl, etc.] were prepd. for
     the treatment of asthma. Thus, 8-phenyloctanoic acid was converted,
     via the alc. and bromide, to 2-[2-(8-phenyloctyl)phenyl]-4,4-
     dimethyloxazoline, which was quaternized and reduced to give
     2-(8-phenyloctyl)benzaldehyde (II). Reaction of II with ClCH2CO2Me
     gave Me trans-3-[2-(8-phenyloctyl)pheny;]-2,3-epoxypropionate, which
     reacted with 2-mercaptobenzoic acid to give Me 2-hydroxy-3-[(2-
     carboxyphenyl)thio]-3-[2-(8-phenyloctyl)phenyl]propionate; sapon. of
     this ester gave 2-HO2CC6H4SCH[CH(OH)CO2H]C6H4(CH2)8Ph-2. Several I
     showed biosignificant activity against leukotriene D4 in contraction
     tests with guinea pig tracheal tissue in vitro.
     120427-55-6P
    RL: BAC (Biological activity or effector, except adverse); SPN
     (Synthetic preparation); THU (Therapeutic use); BIOL (Biological
     study); PREP (Preparation); USES (Uses)
        (prepn. of, as leukotriene antagonist)
     ICM C07C317-46
         C07C323-62; C07C323-56; C07D311-24; A61K031-19; A61K031-215;
          A61K031-35
     25-17 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
     Section cross-reference(s): 1
                                 120427-56-7P
                                                120427-58-9P
     107023-41-6P 120427-55-6P
                                   120427-61-4P
                                                  120427-62-5P
     120427-59-0P
                   120427-60-3P
     120427-63-6P
                    120427-64-7P
                                   120427-65-8P
                                                  120427-66-9P
     120427-67-0P
                    120427-68-1P
                                   120457-38-7P
                                                  134511-28-7P
     134511-29-8P
                    134511-30-1P
                                   134511-31-2P
                                                  134511-32-3P
     134511-33-4P
                   134511-34-5P
                                   134511-35-6P
                                                  134590-76-4P
     RL: BAC (Biological activity or effector, except adverse); SPN
     (Synthetic preparation); THU (Therapeutic use); BIOL (Biological
```

study); PREP (Preparation); USES (Uses)
 (prepn. of, as leukotriene antagonist)

L5 ANSWER 7 OF 18 HCAPLUS COPYRIGHT 1997 ACS

AN 1990:476603 HCAPLUS

DN 113:76603

TI Enzymic resolution of racemic phenylglycidic acid esters in the manufacture of diltiazem

IN Hulshof, Lumbertus Albregt; Roskam, Jan Hendrik

PA Stamicarbon B. V., Neth.

SO Eur. Pat. Appl., 9 pp.

CODEN: EPXXDW

PI EP 343714 A1 891129

DS R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL, SE

AI EP 89-201236 890517

PRAI NL 88-1311 880520

DT Patent

LA English

OS MARPAT 113:76603

GΙ

- AB Racemic phenylglycidate esters ((I), R1 = alkyl; R2 = H, alkyl) used as intermediates in the synthesis of the vasodilator diltiazem are stereospecifically hydrolyzed by microbial hydrolases. The (2R, 3S) ester that remains is then derivatized with an oxirane ring-opening reagent for further processing. Racemic trans-Et (p-methoxyphenyl) glycidate at 99% e.e was recovered.
- IT 128305-69-1P

RL: PREP (Preparation)

(optically pure, prepn. of, enzymic resoln. of racemic phenylglycidic acid esters for, diltiazem synthesis in relation to)

IC ICM C12P041-00

ICS C12P017-02; C07D303-48; C07D281-10

CC 16-2 (Fermentation and Bioindustrial Chemistry)


IT 128305-69-1P

RL: PREP (Preparation)

(optically pure, prepn. of, enzymic resoln. of racemic phenylglycidic acid esters for, diltiazem synthesis in relation to)

- L5 ANSWER 8 OF 18 HCAPLUS COPYRIGHT 1997 ACS
- AN 1990:440161 HCAPLUS
- DN 113:40161
- TI Preparation of (2S,3S)-threo-2-hydroxy-3-[(2-aminophenyl)thio]-3-(4-methoxyphenyl)propionic acid as an intermediate for the synthesis of diltiazem by optical resolution
- IN Giordano, Claudio; Merli, Valeriano; Sagramora, Giorgio; Soriato,

Giorgio Zambon Group S.p.A., Italy PA SO Eur. Pat. Appl., 5 pp. CODEN: EPXXDW EP 353538 A2 900207 ΡI R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE DS ΑI EP 89-113135 890718 PRAI IT 88-21478 880726 DTPatent LА English MARPAT 113:40161 os



- AΒ The title compd. (I) is sepd. from its racemic mixt. by using the diol II (X = H, MeS, O2N, MeSO2) in the molar ratio of 0.5 with respect to the mixt. to be resolved. Racemic-I was treated with (1s,2s)-II (X = Me) to give the appropriate salt which was dild. in H2O and treated with HCl to give I.
- TΤ 127981-91-3P RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (prepn. and decompn. of)
- IC ICM C07C323-36 ICS C07C319-28; C07B057-00
- 25-17 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds) CC
- 128001-76-3P IΤ 127981-91-3P RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (prepn. and decompn. of)
- ANSWER 9 OF 18 HCAPLUS COPYRIGHT 1997 ACS L5
- 1989:219194 HCAPLUS ΑN
- 110:219194 DN

GΙ

- High-performance liquid chromatography method for assay of diltiazem ΤI hydrochloride and its related compounds in bulk drug and finished tablets
- ΑU Lacroix, Pauline M.; Beaulieu, Normand; Cyr, Terry D.; Lovering, Edward G.
- CS
- Bur. Drug Res., Health Prot. Branch, Ottawa, ON, K1A 0L2, Can. J. Pharm. Sci. (1989), 78(3), 243-6 CODEN: JPMSAE; ISSN: 0022-3549 SO
- DT Journal
- LА English
- trans-Diltiazem and 7 known and several unknown related compds. were AΒ sepd. from diltiazem-HCl by HPLC. Min. detectable amts. were <0.1%, except for an intermediate which originates early in the synthetic process, for which the sensitivity is .apprx.2%. The relative std. deviation of the assay procedure is 0.15%. Total related compds. in 4 bulk drug and 4 tablet samples were <0.25%. The sp. rotation of 4 samples of diltiazem-HCl analyzed in duplicate was between +112 and +114.degree.. The UV absorption spectra of all compds. exhibited 2 max., one between 203 and 213 nm and the other between 230 and 244

nm.

IT 120433-69-4

RL: PROC (Process)

(sepn. of, from diltiazem, by HPLC)

CC 64-3 (Pharmaceutical Analysis)
 Section cross-reference(s): 63

IT 42399-40-6 42399-49-5 42399-55-3 84056-02-0 84645-12-5

84645-13-6 **120433-69-4** 

RL: PROC (Process)

(sepn. of, from diltiazem, by HPLC)

L5 ANSWER 10 OF 18 HCAPLUS COPYRIGHT 1997 ACS

AN 1989:212373 HCAPLUS

DN 110:212373

TI Preparation of 2-hydroxy-3-[(carboxyphenyl)thio]propionic acids and analogs as leukotriene antagonists

IN Frazee, James Simpson; Gleason, John Gerald; Hall, Ralph Floyd

PA SmithKline Beckman Corp., USA

SO Eur. Pat. Appl., 45 pp.

CODEN: EPXXDW

PI EP 296732 A1 881228

DS R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE

AI EP 88-305188 880607

PRAI US 87-66588 870624

DT Patent

LA English

OS MARPAT 110:212373

GΙ

CHYS (0) 
$$q$$
 (CR<sup>4</sup>R<sup>5</sup>)  $q$ W

CHS

CHS

CHS

(CH2) 8Ph II

The title compds. [I; A = H, Cl-4 alkyl, Cl-4 alkoxy, halo, OH, NO2, NH2; R1 = H, MTc(CH2)bLa (Q); R2 = A, Q; R4, R5 = H, Cl-4 alkyl; L, T = O, S; M = Cl-4 alkyl, CF3, HC.tplbond.C, CH2:CMe, furanyl, thienyl, cyclohexyl, (un)substituted Ph; W = 2-carboxy-4-oxo-8-propyl-4H-1-benzopyran-7-yl, (un)substituted Ph, pyridinyl, pyrimidinyl; Y = R3CO, Z(CH2)p(CHX)n; R3 = Cl-6 alkoxy, aryloxy, OH, NH2; X = H, Cl-4 alkyl, Cl-4 alkoxy, OH, F; Z = R3CO, tetrazolyl; a, c, n, = 0, 1; b = 3-14; d = 0-6; p, q = 0-2] and their pharmaceutically acceptable salts were prepd. as leukotriene antagonists. HO(CH2)4CH.tplbond.CH was esterified with 4-MeC6H4SO2Cl and treated with PhC.tplbond.CH to give PhC.tplbond.C(CH2)4C.tplbond.CH. The latter was arylated with 2-BrC6H4CHO and the product was hydrogenated to give 2-(8-phenyloctyl)benzaldehyde which was condensed with ClCH2CO2Me in

the presence of NaOMe to give Me trans-2,3-epoxy-3-[2-(8-phenyloctyl)phenyl]propionate. The latter was treated with 2-HSC6H4CO2H in MeOH in the presence of Et3N and the product sapond. to give title compd. II. II inhibited leukotriene-induced contraction of guinea pig tracheal tissue prepns. with -log KB of 5.5. An aerosol soln. for nebulizer use was prepd. from 1-10 mg II and isotonic saline soln.

IT 120427-55-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of, as leukotrienes antagonist)

IC ICM C07C149-40

ICS C07C149-273; C07C149-36; A61K031-19

- CC 25-17 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
   Section cross-reference(s): 1
- 120427-57-8P 120427-58-9P ΙT 120427-55-6P 120427-56-7P 120427-59-0P 120427-60-3P 120427-61-4P 120427-62-5P 120427-63-6P 120427-64-7P 120427-65-8P 120427-66-9P 120427-67-0P 120427-68-1P 120427-69-2P 120427-70-5P

120427-71-6P 120457-38-7P

RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of, as leukotrienes antagonist)

- L5 ANSWER 11 OF 18 HCAPLUS COPYRIGHT 1997 ACS
- AN 1988:549900 HCAPLUS
- DN 109:149900
- TI The selective monobenzylidenation of some monosaccharides and their derivatives with .alpha.,.alpha.-dimethoxytoluene
- AU Patroni, Joseph J.; Stick, Robert V.; Skelton, Brian W.; White, Allan H.
- CS Sch. Chem., Univ. West. Australia, Nedlands, 6009, Australia
- SO Aust. J. Chem. (1988), 41(1), 91-102 CODEN: AJCHAS; ISSN: 0004-9425
- DT Journal
- LA English
- OS CASREACT 109:149900

GΙ

AB The treatment of a no. of monosaccharides and their derivs. with .alpha.,.alpha.-dimethoxytoluene and an acid catalyst in DMF at about 80.degree. can lead to selective benzylidenation, e.g., Me .alpha.-D-mannopyranoside gives mainly Me 4,6-O-benzylidene-.alpha.-D-mannoside (I), together with 2 other minor 2,3-monobenzylidene

derivs. and 2 minor 2,3:4,6-dibenzylidene derivs. The treatment of various other pyranoses and pyranosides is also described. In addn. a 1H NMR study of the acid transformation of some of the above .alpha.-D-mannosides is reported, together with the single-crystal x-ray diffraction structure of Me (S)-2,3-0-benzylidene-.alpha.-Dmannopyranoside (II). 55651-99-5P RL: SPN (Synthetic preparation); PREP (Preparation)

- - (prepn. of)
- 33-3 (Carbohydrates) CC

Section cross-reference(s): 75

- ΙT 3162-96-7P 4288-93-1P 14086-06-7P 14155-23-8P 17063-22-8P 30688-66-5P 40653-36-9P 40653-37-0P **55651-99-5P** 73395-15-0P 85761-43-9P 116562-85-7P 116562-86-8P 116562-87-9P
  - RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)
- ANSWER 12 OF 18 HCAPLUS COPYRIGHT 1997 ACS L5
- 1988:75759 HCAPLUS AN
- 108:75759 DN
- Thioglycosides of N-acetylneuraminic acid. Part 4. Synthesis of ΤI 3-S-(5-acetamido-3,5-dideoxy-D-glycero-.alpha.-D-galacto-2nonulopyranosylonic acid)-3-thio-galactopyranose derivatives
- Kanie, Osamu; Nakamura, Junko; Itoh, Yukiyasu; Kiso, Makoto; ΑU Hasegawa, Akira
- Dep. Agric. Chem., Gifu Univ., Gifu, 501-11, Japan CS
- J. Carbohydr. Chem. (1987), 6(1), 117-28 so CODEN: JCACDM; ISSN: 0732-8303
- DTJournal
- LΆ English
- CASREACT 108:75759 OS

GΙ

AB 3-S-.alpha.-D-Neuraminyl-(2.fwdarw.3)-D-galactose derivs. were prepd. As the glycosyl acceptors, 4,6-O-ethylidene-1,2-O-isopropylidene-3-O-trifluoromethanesulfonyl-.alpha.-D-gulopyranose (I) and 1,2-di-O-acetyl-4,6-O-isopropylidene-3-O-trifluoromethanesulfonyl-.beta.-D-gulopyranose (II) were prepd. from 4,6-O-ethylidene-1,2-O-isopropylidene-.alpha.-D-galactopyranose in several steps. Condensation of I or II with the sodium salt of Me 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-2-thio-D-glycero-.alpha.-D-galacto-2-nonulopyranosonate gave the corresponding 3-S-(N-acetyl-.alpha.-D-neuraminyl)-3-thio-D-galactose derivs. III and IV (R2 = Me2C). The latter was converted, via O-deisopropylidenation and subsequent acetylation, into the desired product IV (R = Ac).

IT 112670-08-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (prepn. and acetylation of)

CC 33-8 (Carbohydrates)

IT 112670-08-3P 112670-15-2P

- L5 ANSWER 13 OF 18 HCAPLUS COPYRIGHT 1997 ACS
- AN 1986:627147 HCAPLUS
- DN 105:227147
- TI Studies in sugar chemistry. Part III. Regioselective heterogeneous O-deacylation of polyacylated sugars
- AU Herzig, Jacob; Nudelman, Abraham
- CS Teva Pharm. Ind. Ltd., Petach Tiqwa, Israel
- SO Carbohydr. Res. (1986), 153(1), 162-7

CODEN: CRBRAT; ISSN: 0008-6215

```
DT
     Journal
LA
     English
OS
     CASREACT 105:227147
    Methanolysis of polyacylated sugars is catalyzed by MgO or Al2O3.
ÆΒ
     MgO is a mild, nonselective deacylating agent, whereas the
     reactivity of Al203 may be modulated. By choosing the appropriate
     catalyst and conditions, deacylation at the anomeric position may be
     readily effected regioselectively. Thus, MgO-catalyzed methanolysis
     of 1,2,3-tri-O-acetyl-4,6-O-ethylidene-.beta.-D-glucopyranose (I) 30
     min at room temp. gave 93% 4,6-O-ethylidene-D-glucopyranose whereas
     Al203-catalyzed methanolysis of I 10h at 60.degree. gave 61%
     2,3-di-O-acetyl-4,6-O-ethylidene-D-glucopyranose.
IT
     105453-42-7P
     RL: SPN (Synthetic preparation); PREP (Preparation)
        (prepn. of, by O-deacylation, catalysts for)
CC
     33-1 (Carbohydrates)
                           57-50-1P, preparation 58-86-6P,
IT
     50-99-7P, preparation
     preparation 709-50-2P 1824-94-8P 55018-54-7P 105453-33-6P
                  105453-35-8P 105453-37-0P 105453-38-1P
     105453-34-7P
                   105453-40-5P
                                   105453-41-6P 105453-42-7P
     105453-39-2P
     105453-43-8P
     RL: SPN (Synthetic preparation); PREP (Preparation)
        (prepn. of, by O-deacylation, catalysts for)
    ANSWER 14 OF 18 HCAPLUS COPYRIGHT 1997 ACS
L5
    1986:110035 HCAPLUS
AN
DN
     104:110035
TI
     Studies in sugar chemistry. 2. A simple method for O-deacylation
     of polyacylated sugars
     Herzig, Jacob; Nudelman, Abraham; Gottlieb, Hugo E.; Fischer, Bilha
ΑU
CS
     Teva Pharm. Ind. Ltd., Petach Tiqva, Israel
     J. Org. Chem. (1986), 51(5), 727-30
SO
     CODEN: JOCEAH; ISSN: 0022-3263
DT
    Journal
LA
    English
OS
     CASREACT 104:110035; CJACS
AB
     Total solvolytic O-deacylation of polyacylated sugars is readily
     accomplished upon stirring for 15 min-6 h a soln. of a sugar in MeOH
     in the presence of a catalytic amt. of cyanide. The reaction
     proceeds in high yields, under neutral conditions, at room temp.
     The overall rate of the reaction, readily followed by observing the
     changes in the 1H 300 MHz NMR spectra, is greatly influenced by the
     substituent at the anomeric position in the order of 1-OH .mchgt.
     1-OAc .mchgt..mchgt. 1-OR.
TT
     100021-32-7
     RL: RCT (Reactant)
        (intermediate, in O-deacylation of, triacetyl deriv. with
        potassium cyanide and methanol)
CC
     33-1 (Carbohydrates)
IT
     100021-32-7
                  100021-33-8
     RL: RCT (Reactant)
        (intermediate, in O-deacylation of, triacetyl deriv. with
        potassium cyanide and methanol)
     ANSWER 15 OF 18 HCAPLUS COPYRIGHT 1997 ACS
L5
     1985:542026 HCAPLUS
ΑN
```

```
103:142026
DN
     8-Chloro-1,5-benzothiazepine derivatives
ΤI
     Takeda, Mikio; Ohishi, Tokuro; Nakajima, Hiromichi; Nagao, Taku
IN
     Tanabe Seiyaku Co., Ltd., Japan
PA
     Eur. Pat. Appl., 61 pp.
SO
     CODEN: EPXXDW
     EP 127882 A1 841212
PΙ
     R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE
DS
     EP 84-106187 840530
ΑI
PRAI GB 83-15364 830603
     GB 84-983 840114
DT
     Patent
LΑ
     English
GΙ
```

$$\begin{array}{c} \text{OMe} \\ \text{Cl} \\ \text{N} \\ \text{R}^1\text{R}^2\text{NCH}_2\text{CH}_2 \end{array}$$

Title compds. I (R = H, alkyl, acyl; R1, R2 = alkyl) were prepd. Thus, (+)-cis-2-(4-methoxyphenyl)-3-hydroxy-8-chloro-2,3-dihydro-1,5-benzothiazepin-4(5H)-one, prepd. in 4 steps from 5,2-Cl(H2N)C6H3SH and Me (.+-.)-trans-3-(4-methoxyphenyl)glycidate, was alkylated with Me2NCH2CH2Cl.HCl to give (+)-cis-I (R = H, R1 = R2 = Me), which was acetylated with Ac2O/pyridine to give (+)-cis-I (R = Ac, R1 = R2 = Me) (II). II maleate at 30 mg/kg orally to spontaneously hypertensive rats decreased systolic blood pressure by .gtoreq.60 mm Hg at both 1 and 4 h after dosing. The cerebral vasodilating activity of II.HCl was 25-fold that of papaverine.

IC C07D281-10; A61K031-55

CC 28-22 (Heterocyclic Compounds (More Than One Hetero Atom))

Ι

L5 ANSWER 16 OF 18 HCAPLUS COPYRIGHT 1997 ACS

AN 1982:545161 HCAPLUS

DN 97:145161

TI Amino sugars. 132. Preparation of a glycosyl chloride suitable for synthesis of N-glycoprotein "core" pentasaccharide

AU Liu, Charng Ming; Warren, Christopher D.; Blieszner, Kathleen C.; Jeanloz, Roger W.

CS Dep. Biol. Chem., Harvard Med. Sch., Boston, MA, 02114, USA

```
Carbohydr. Res. (1982), 104(2), C20-C22
SO
     CODEN: CRBRAT; ISSN: 0008-6215
     Journal
DT
     English
LA
     4-0-Benzyl-3-0-(2-butenyl)-6-0-(tert-butyldiphenylsilyl)-2-0-(p-
AΒ
     nitrobenzoyl) - .alpha. - D-glycopyranosyl chloride, suitable for the
     synthesis of N-glycoprotein core pentasaccharide, was prepd. from
     3-O-(2-butenyl)-D-glucose in 9 steps.
     83158-08-1P
TΤ
     RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
        (prepn. and acetylation of)
CC
     33-2 (Carbohydrates)
ΙT
     83158-08-1P
     RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
        (prepn. and acetylation of)
     ANSWER 17 OF 18 HCAPLUS COPYRIGHT 1997 ACS
L5
     1975:156596 HCAPLUS
AN
DN
     82:156596
     Dibutylstannylene derivatives of sugar
TI
     David, Serge; Thieffry, Annie
ΑU
     Lab. Chim. Org. Multifonct., Univ. Paris-Sud, Orsay, Fr.
CS
     C. R. Hebd. Seances Acad. Sci., Ser. C (1974), 279(25), 1045-7
SO
     CODEN: CHDCAQ
DT
     Journal
     French
LA
GT
     For diagram(s), see printed CA Issue.
     Seven diols I, .alpha.- and .beta.-II, III, (R = H) .alpha.- and
AB
     .beta.-IV (R1 = R2 = H, R3 = Me; R1 = Me, R2 = R3 = H) were treated
     with Bu2SnO. The cis diols I and .alpha.-IV (R = R2 = H, R3 = Me)
     gave 30% of the dibutylstannylenes I (RR = SnBu2) and .alpha.-IV
     (RR2 = SnBu2, R3 = Me). The trans diols II, III, and .alpha. - and
     .beta.-IV (R1 = Me, R2 = R3 = H) gave 8-63\% II and III (RR = SnBu2)
     and IV (R1 = Me, R2R3 = SnBu2).
ΙT
     55651-99-5
     RL: RCT (Reactant)
        (reaction with dibutyltin oxide, stannylenes by)
CC
     33-2 (Carbohydrates)
     3162-96-7
                 10368-81-7
                              14155-23-8 53429-46-2 55651-99-5
TΤ
                  55700-62-4
     55700-61-3
     RL: RCT (Reactant)
        (reaction with dibutyltin oxide, stannylenes by)
     ANSWER 18 OF 18 HCAPLUS COPYRIGHT 1997 ACS
L5
     1973:466331 HCAPLUS
AN
DN
     79:66331
     Synthesis of 1,5-benzothiazepine derivatives. IV. Resolution of
ΤI
     dl-cis-3-acetoxy-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(p-
     methoxyphenyl)-1,5-benzothiazepin-4(5H)-one hydrochloride
     Inoue, Hirozumi; Takeo, Satoshi; Kawazu, Mitsutaka; Kugita, Hiroshi
AU
     Org. Chem. Res. Lab., Tanabe Seiyaku Co., Ltd., Toda, Japan
CS
     Yakugaku Zasshi (1973), 93(6), 729-32
SO
     CODEN: YKKZAJ
DT
     Journal
LΑ
     Japanese
GΙ
     For diagram(s), see printed CA Issue.
AB
     Prepn. by cyclization of cinchonidine-resolved I of
```

```
(+)-cis-3-acetoxy-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(p-
     methoxyphenyl)-1,5-benzothiazepin-4(5H)-one [(+)-II].HCl with potent
     coronary vasodilatory activity is described. Attempted resolution
     of II with various optically active acids was unsuccessful.
     42399-56-4P
     RL: SPN (Synthetic preparation); PREP (Preparation)
        (prepn. of)
     28-24 (Heterocyclic Compounds (More Than One Hetero Atom))
     107-99-3P
                 33286-22-5P
                              42399-40-6P 42399-41-7P
                                                            42399-44-0P
     42399-45-1P
                   42399-46-2P
                                 42399-47-3P
                                               42399-48-4P
                                                              42399-49-5P
     42399-50-8P
                   42399-51-9P
                                 42399-53-1P
                                                42399-54-2P
     42399-56-4P
                   42399-57-5P
                                 42489-24-7P
     RL: SPN (Synthetic preparation); PREP (Preparation)
        (prepn. of)
=> fil caold
FILE 'CAOLD' ENTERED AT 09:52:37 ON 22 MAY 1997
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 1997 AMERICAN CHEMICAL SOCIETY (ACS)
FILE COVERS 1957-1966
FILE LAST UPDATED: 30 OCT 91 (910803/ED)
  To help control your online searching costs, consider using the
  HCAOLD File when conducting SmartSELECT searches with large
  numbers of terms.
  This file contains CAS Registry Numbers for easy and accurate
  substance identification.
                 Searchable and selectable accession numbers,
  NEW TO CAOLD:
                 hit-term highlighting, and the HITSTR display
                 format. See NEWS for details.
=> d his 16
     (FILE 'CAOLD' ENTERED AT 09:50:53 ON 22 MAY 1997)
              3 S L4
     FILE
          'REGISTRY' ENTERED AT 09:51:01 ON 22 MAY 1997
                                /09:51:\12 ON 22 MI(Y 1997
     FILE
          'REGISTRY'
                     ENTERED AT
                                        Òon 22 M∡AY 1997
           HCAPLUS' ENTERED AT 09:51:53
     FILE
                          AT 0/9:52:37 ON 22 MAY 1997
          'CAOLD' ENTERED
=> d all 1-3
     ANSWER 1 OF 3 COPYRIGHT 1997 ACS
     CA58:9223c CAOLD
IT 100323-59-9 103101-90-2 106740-81-2
     ANSWER 2 OF 3 COPYRIGHT 1997 ACS
     CA58:1531q CAOLD
```

IT

CC

IT

L6

AN

L6

AN

TТ

98693-62-0 **101173-91-5** 105042-76-0

ANSWER 3 OF 3 COPYRIGHT 1997 ACS CA57:11292c CAOLD L6

AN

101173-91-5 103101-90-2 IT